These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

689 related items for PubMed ID: 33530704

  • 1. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
    Berg DD, Samsky MD, Velazquez EJ, Duffy CI, Gurmu Y, Braunwald E, Morrow DA, DeVore AD.
    Circ Heart Fail; 2021 Feb; 14(2):e007034. PubMed ID: 33530704
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E, PIONEER-HF Investigators.
    N Engl J Med; 2019 Feb 07; 380(6):539-548. PubMed ID: 30415601
    [Abstract] [Full Text] [Related]

  • 3. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ, PIONEER-HF Investigators.
    JAMA Cardiol; 2020 Feb 01; 5(2):202-207. PubMed ID: 31825471
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.
    Berg DD, Braunwald E, DeVore AD, Lala A, Pinney SP, Duffy CI, Gurmu Y, Velazquez EJ, Morrow DA.
    JACC Heart Fail; 2020 Oct 01; 8(10):834-843. PubMed ID: 32800511
    [Abstract] [Full Text] [Related]

  • 5. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
    Morrow DA, Velazquez EJ, Desai AS, DeVore AD, Lepage S, Park JG, Sharma K, Solomon SD, Starling RC, Ward JH, Williamson KM, Zieroth S, Hernandez AF, Mentz RJ, Braunwald E.
    J Am Coll Cardiol; 2024 Mar 26; 83(12):1123-1132. PubMed ID: 38508844
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial.
    Berardi C, Braunwald E, Morrow DA, Mulder HS, Duffy CI, O'Brien TX, Ambrosy AP, Chakraborty H, Velazquez EJ, DeVore AD, PIONEER-HF Investigators.
    JACC Heart Fail; 2020 Oct 26; 8(10):859-866. PubMed ID: 32919915
    [Abstract] [Full Text] [Related]

  • 7. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
    Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E.
    Am Heart J; 2018 Apr 26; 198():145-151. PubMed ID: 29653636
    [Abstract] [Full Text] [Related]

  • 8. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, Shi V, Zhao Z, Cowie MR, PARALLAX Investigators and Committee members.
    JAMA; 2021 Nov 16; 326(19):1919-1929. PubMed ID: 34783839
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
    Ambrosy AP, Braunwald E, Morrow DA, DeVore AD, McCague K, Meng X, Duffy CI, Rocha R, Velazquez EJ, PIONEER-HF Investigators.
    J Am Coll Cardiol; 2020 Sep 01; 76(9):1034-1048. PubMed ID: 32854838
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
    Jain AR, Aggarwal RK, Rao NS, Billa G, Kumar S.
    Indian Heart J; 2020 Sep 01; 72(6):535-540. PubMed ID: 33357641
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
    Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, Sharma K, Starling RC, Velazquez EJ, Williamson KM, Desai AS, Zieroth S, Solomon SD, Braunwald E, PARAGLIDE-HF Investigators.
    J Am Coll Cardiol; 2023 Jul 04; 82(1):1-12. PubMed ID: 37212758
    [Abstract] [Full Text] [Related]

  • 13. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE, Claggett BL, Wolsk E, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer MA, Desai AS, Lund LH, Kober L, Anand I, Merkely B, Senni M, Shi V, Rizkala A, Lefkowitz M, McMurray JJV, Solomon SD.
    Circ Heart Fail; 2021 Mar 04; 14(3):e008052. PubMed ID: 33706551
    [Abstract] [Full Text] [Related]

  • 14. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
    Ehteshami-Afshar S, Mooney L, Dewan P, Desai AS, Lang NN, Lefkowitz MP, Petrie MC, Rizkala AR, Rouleau JL, Solomon SD, Swedberg K, Shi VC, Zile MR, Packer M, McMurray JJV, Jhund PS, Hawkins NM.
    J Am Heart Assoc; 2021 Feb 16; 10(4):e019238. PubMed ID: 33522249
    [Abstract] [Full Text] [Related]

  • 15. Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial.
    Bocchi EA, Echeverria LE, Demacq C, de Barros E Silva PGM, Mazza Barbosa L, Chiang LM, Damiani L, Morillo CA, Kevorkian R, Ramires F, Bahit MC, Ferrari A, Chavez-Mendoza A, Magaña-Serrano JA, McMurray JJV, Gimpelewicz C, Lopes RD, PARACHUTE-HF Investigators.
    JACC Heart Fail; 2024 Aug 16; 12(8):1473-1486. PubMed ID: 39111953
    [Abstract] [Full Text] [Related]

  • 16. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
    Mitchell GF, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, Abbas CA, Desai AS, EVALUATE-HF Investigators*.
    Circ Heart Fail; 2021 Mar 16; 14(3):e007891. PubMed ID: 33663237
    [Abstract] [Full Text] [Related]

  • 17. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
    Mann DL, Greene SJ, Givertz MM, Vader JM, Starling RC, Ambrosy AP, Shah P, McNulty SE, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, Mohammed SF, Gilotra NA, DeVore AD, Gorodeski EZ, Desvigne-Nickens P, Hernandez AF, Braunwald E, LIFE Investigators.
    JACC Heart Fail; 2020 Oct 16; 8(10):789-799. PubMed ID: 32641226
    [Abstract] [Full Text] [Related]

  • 18. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan Ö, Dukat A, Lefkowitz MP, McMurray JJ.
    Circ Heart Fail; 2016 Mar 16; 9(3):e002744. PubMed ID: 26915374
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H, Momomura S, Saito Y, Ito H, Yamamoto K, Ohishi T, Okino N, Guo W.
    J Cardiol; 2017 Sep 16; 70(3):225-231. PubMed ID: 28024961
    [Abstract] [Full Text] [Related]

  • 20. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong J, Shi VC, Solomon SD.
    J Am Coll Cardiol; 2016 Dec 06; 68(22):2425-2436. PubMed ID: 27908347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.